In general, CONVULX® is well tolerated by patients. Side effects are possible mainly with the concentration of valproic acid in plasma above 100 mg / l or with combination therapy.
Gastrointestinal tract: nausea, vomiting, gastralgia, decreased or increased appetite, diarrhea, hepatitis, constipation, pancreatitis, up to severe lesions with a fatal outcome (in the first 6 months of treatment, usually 2-12 weeks).
central nervous system: tremor, changes in behavior, mood or mental state (depression, fatigue, hallucinations, aggressiveness, hyperactivity, psychoses, unusual arousal, motor anxiety or irritability), ataxia, dizziness, drowsiness, headache, encephalopathy, dysarthria, enuresis, stupor , impaired consciousness, coma.
From the sense organs: diplopia, nystagmus, flashing of "flies" before the eyes.
On the part of the organs of hematopoiesis and the system of hemostasis: anemia, leukopenia; thrombocytopenia, decreased fibrinogen and platelet aggregation leading to the development of hypocoagulation (accompanied by prolonged bleeding time, petechial hemorrhages, bruising, bruising, bleeding).
From the side of metabolism: decrease or increase in body weight.
Allergic reactions: skin rash, hives, angioedema, photosensitivity, malignant exudative erythema (Stevens-Johnson syndrome).
Laboratory indicators: hypercreatininaemia, hyperammonemia, hyperbilirubinemia, hyperglycinemia, insignificant increase in the activity of "liver" transaminases, lactate dehydrogenase (dose-dependent).